An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-12

AUTHORS

Stanley Cohen, Jose L. Pablos, Karel Pavelka, Gerard Anton Müller, Alan Matsumoto, Alan Kivitz, Hui Wang, Eswar Krishnan

ABSTRACT

BACKGROUND: ABP 501 was evaluated in a phase 3 single-arm, open-label extension (OLE) study to collect additional safety and efficacy data in patients with rheumatoid arthritis (RA). METHODS: Subjects completing the final visit in the parent phase 3 randomized, double-blind, controlled equivalence study comparing the efficacy and safety of the biosimilar ABP 501 with adalimumab reference product (RP) were enrolled in this open-label extension (OLE) study. All subjects received 40 mg ABP 501 every other week for 68 weeks. Key safety endpoints included treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and anti-drug antibody (ADA) incidences. Efficacy endpoints included ACR20 (at least 20% improvement in American College of Rheumatology core set measurements from baseline) and Disease Activity Score 28-joint count C-reactive protein (DAS28-CRP) change from baseline. RESULTS: Among 466/467 patients treated with ABP 501, 229 transitioned from the ABP 501 arm of the parent study (ABP 501/ABP 501) and 237 from the adalimumab RP arm (RP/ABP 501); 412/467 (88.2%) patients completed the study. The overall TEAE incidence was 63.7% (297/466); grade ≥ 3 TEAE incidence was 9.0% (42/466). The incidence of TEAEs leading to discontinuation of investigational product was 3.6% (17/466). The SAE incidence was 9.9% (46/466). Overall, 18.2% (85/466) of subjects developed binding ADAs and 6.9% (32/466) developed neutralizing ADAs in the OLE study. The ACR20 response rate was 73.3% (340/464 subjects) at OLE baseline, and 78.8% (327/415 subjects) at week 70 of the OLE study. The overall mean DAS28-CRP change from the parent study baseline was - 2.25 at the OLE study baseline (n = 440), - 2.36 at week 4 (n = 463), - 2.41 at week 24 (n = 450), - 2.55 at week 48 (n = 433), and - 2.60 at week 70 (n = 412). Efficacy was maintained throughout the study. CONCLUSIONS: Efficacy previously demonstrated in the parent study was maintained in this OLE study with no new safety findings. Long-term safety, immunogenicity, and efficacy were similar in the ABP 501/ABP 501 and RP/ABP 501 groups. The single switch from RP to ABP 501 did not impact immunogenicity. TRIAL REGISTRATION: ClinicalTrial.gov, NCT02114931. More... »

PAGES

84

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s13075-019-1857-3

DOI

http://dx.doi.org/10.1186/s13075-019-1857-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1113057001

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30922373


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Metroplex Clinical Research Center", 
          "id": "https://www.grid.ac/institutes/grid.477482.a", 
          "name": [
            "Internal Medicine, Rheumatology Division, Metroplex Clinical Research Center, 8144 Walnut Hill Lane, Suite 800, 75231, Dallas, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cohen", 
        "givenName": "Stanley", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hospital Universitario 12 De Octubre", 
          "id": "https://www.grid.ac/institutes/grid.144756.5", 
          "name": [
            "Instituto de Investigaci\u00f3n Hospital 12 de Octubre, Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pablos", 
        "givenName": "Jose L.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Revmatologick\u00fd \u00fastav", 
          "id": "https://www.grid.ac/institutes/grid.418965.7", 
          "name": [
            "Institute of Rheumatology, Prague 2, Czech Republic"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pavelka", 
        "givenName": "Karel", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Abteilung.f\u00fcr Nephrologie und Rheumatologie, G\u00f6ttingen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "M\u00fcller", 
        "givenName": "Gerard Anton", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Arthritis and Rheumatism Associates", 
          "id": "https://www.grid.ac/institutes/grid.490547.b", 
          "name": [
            "Arthritis and Rheumatism Associates, Wheaton, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Matsumoto", 
        "givenName": "Alan", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Abteilung f\u00fcr Nephrologie und Rheumatologie, G\u00f6ttingen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kivitz", 
        "givenName": "Alan", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amgen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "Biosimilars Development, Amgen Inc., Thousand Oaks, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wang", 
        "givenName": "Hui", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amgen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "Biosimilars Development, Amgen Inc., Thousand Oaks, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Krishnan", 
        "givenName": "Eswar", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1093/rheumatology/ket260", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000218995"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/art.22214", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009901742"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.semarthrit.2016.01.002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012251139"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/rheumatology/ker124", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012965699"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1586/1744666x.2015.1090313", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013216059"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1529-0131(199809)41:9<1552::aid-art5>3.0.co;2-w", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017993092"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/annrheumdis-2016-209166", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023109204"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/ar3147", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024364202", 
          "https://doi.org/10.1186/ar3147"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.semarthrit.2016.01.001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032526040"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.semarthrit.2015.04.002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037699729"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40259-016-0184-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038300105", 
          "https://doi.org/10.1007/s40259-016-0184-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40259-016-0184-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038300105", 
          "https://doi.org/10.1007/s40259-016-0184-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11926-016-0601-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040002812", 
          "https://doi.org/10.1007/s11926-016-0601-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11926-016-0601-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040002812", 
          "https://doi.org/10.1007/s11926-016-0601-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40259-016-0185-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042463549", 
          "https://doi.org/10.1007/s40259-016-0185-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40259-016-0185-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042463549", 
          "https://doi.org/10.1007/s40259-016-0185-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0049-0172(90)90060-s", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045775208"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078771680", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jaad.2016.12.014", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084083514"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40259-017-0218-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085050557", 
          "https://doi.org/10.1007/s40259-017-0218-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40259-017-0218-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085050557", 
          "https://doi.org/10.1007/s40259-017-0218-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/annrheumdis-2016-210459", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085872012"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/bjd.15857", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1090920617"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/bjd.15857", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1090920617"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1106025459", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-12", 
    "datePublishedReg": "2019-12-01", 
    "description": "BACKGROUND: ABP 501 was evaluated in a phase 3 single-arm, open-label extension (OLE) study to collect additional safety and efficacy data in patients with rheumatoid arthritis (RA).\nMETHODS: Subjects completing the final visit in the parent phase 3 randomized, double-blind, controlled equivalence study comparing the efficacy and safety of the biosimilar ABP 501 with adalimumab reference product (RP) were enrolled in this open-label extension (OLE) study. All subjects received 40\u2009mg ABP 501 every other week for 68\u2009weeks. Key safety endpoints included treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and anti-drug antibody (ADA) incidences. Efficacy endpoints included ACR20 (at least 20% improvement in American College of Rheumatology core set measurements from baseline) and Disease Activity Score 28-joint count C-reactive protein (DAS28-CRP) change from baseline.\nRESULTS: Among 466/467 patients treated with ABP 501, 229 transitioned from the ABP 501 arm of the parent study (ABP 501/ABP 501) and 237 from the adalimumab RP arm (RP/ABP 501); 412/467 (88.2%) patients completed the study. The overall TEAE incidence was 63.7% (297/466); grade\u2009\u2265\u20093 TEAE incidence was 9.0% (42/466). The incidence of TEAEs leading to discontinuation of investigational product was 3.6% (17/466). The SAE incidence was 9.9% (46/466). Overall, 18.2% (85/466) of subjects developed binding ADAs and 6.9% (32/466) developed neutralizing ADAs in the OLE study. The ACR20 response rate was 73.3% (340/464 subjects) at OLE baseline, and 78.8% (327/415 subjects) at week 70 of the OLE study. The overall mean DAS28-CRP change from the parent study baseline was -\u20092.25 at the OLE study baseline (n\u2009=\u2009440), -\u20092.36 at week 4 (n\u2009=\u2009463), -\u20092.41 at week 24 (n\u2009=\u2009450), -\u20092.55 at week 48 (n\u2009=\u2009433), and -\u20092.60 at week 70 (n\u2009=\u2009412). Efficacy was maintained throughout the study.\nCONCLUSIONS: Efficacy previously demonstrated in the parent study was maintained in this OLE study with no new safety findings. Long-term safety, immunogenicity, and efficacy were similar in the ABP 501/ABP 501 and RP/ABP 501 groups. The single switch from RP to ABP 501 did not impact immunogenicity.\nTRIAL REGISTRATION: ClinicalTrial.gov, NCT02114931.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s13075-019-1857-3", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1297499", 
        "issn": [
          "1478-6354", 
          "1478-6362"
        ], 
        "name": "Arthritis Research & Therapy", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "21"
      }
    ], 
    "name": "An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis", 
    "pagination": "84", 
    "productId": [
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s13075-019-1857-3"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1113057001"
        ]
      }, 
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "9c2f7819fbddef15635892850b461d152ea07841efcdb7f2f174243af446fe38"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101154438"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30922373"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s13075-019-1857-3", 
      "https://app.dimensions.ai/details/publication/pub.1113057001"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-16T06:25", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000377_0000000377/records_106834_00000002.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs13075-019-1857-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s13075-019-1857-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s13075-019-1857-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s13075-019-1857-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s13075-019-1857-3'


 

This table displays all metadata directly associated to this object as RDF triples.

189 TRIPLES      21 PREDICATES      49 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s13075-019-1857-3 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author Ndb3cd92bb1504673934c3101d35fc0e0
4 schema:citation sg:pub.10.1007/s11926-016-0601-0
5 sg:pub.10.1007/s40259-016-0184-3
6 sg:pub.10.1007/s40259-016-0185-2
7 sg:pub.10.1007/s40259-017-0218-5
8 sg:pub.10.1186/ar3147
9 https://app.dimensions.ai/details/publication/pub.1078771680
10 https://app.dimensions.ai/details/publication/pub.1106025459
11 https://doi.org/10.1002/1529-0131(199809)41:9<1552::aid-art5>3.0.co;2-w
12 https://doi.org/10.1002/art.22214
13 https://doi.org/10.1016/0049-0172(90)90060-s
14 https://doi.org/10.1016/j.jaad.2016.12.014
15 https://doi.org/10.1016/j.semarthrit.2015.04.002
16 https://doi.org/10.1016/j.semarthrit.2016.01.001
17 https://doi.org/10.1016/j.semarthrit.2016.01.002
18 https://doi.org/10.1093/rheumatology/ker124
19 https://doi.org/10.1093/rheumatology/ket260
20 https://doi.org/10.1111/bjd.15857
21 https://doi.org/10.1136/annrheumdis-2016-209166
22 https://doi.org/10.1136/annrheumdis-2016-210459
23 https://doi.org/10.1586/1744666x.2015.1090313
24 schema:datePublished 2019-12
25 schema:datePublishedReg 2019-12-01
26 schema:description BACKGROUND: ABP 501 was evaluated in a phase 3 single-arm, open-label extension (OLE) study to collect additional safety and efficacy data in patients with rheumatoid arthritis (RA). METHODS: Subjects completing the final visit in the parent phase 3 randomized, double-blind, controlled equivalence study comparing the efficacy and safety of the biosimilar ABP 501 with adalimumab reference product (RP) were enrolled in this open-label extension (OLE) study. All subjects received 40 mg ABP 501 every other week for 68 weeks. Key safety endpoints included treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and anti-drug antibody (ADA) incidences. Efficacy endpoints included ACR20 (at least 20% improvement in American College of Rheumatology core set measurements from baseline) and Disease Activity Score 28-joint count C-reactive protein (DAS28-CRP) change from baseline. RESULTS: Among 466/467 patients treated with ABP 501, 229 transitioned from the ABP 501 arm of the parent study (ABP 501/ABP 501) and 237 from the adalimumab RP arm (RP/ABP 501); 412/467 (88.2%) patients completed the study. The overall TEAE incidence was 63.7% (297/466); grade ≥ 3 TEAE incidence was 9.0% (42/466). The incidence of TEAEs leading to discontinuation of investigational product was 3.6% (17/466). The SAE incidence was 9.9% (46/466). Overall, 18.2% (85/466) of subjects developed binding ADAs and 6.9% (32/466) developed neutralizing ADAs in the OLE study. The ACR20 response rate was 73.3% (340/464 subjects) at OLE baseline, and 78.8% (327/415 subjects) at week 70 of the OLE study. The overall mean DAS28-CRP change from the parent study baseline was - 2.25 at the OLE study baseline (n = 440), - 2.36 at week 4 (n = 463), - 2.41 at week 24 (n = 450), - 2.55 at week 48 (n = 433), and - 2.60 at week 70 (n = 412). Efficacy was maintained throughout the study. CONCLUSIONS: Efficacy previously demonstrated in the parent study was maintained in this OLE study with no new safety findings. Long-term safety, immunogenicity, and efficacy were similar in the ABP 501/ABP 501 and RP/ABP 501 groups. The single switch from RP to ABP 501 did not impact immunogenicity. TRIAL REGISTRATION: ClinicalTrial.gov, NCT02114931.
27 schema:genre research_article
28 schema:inLanguage en
29 schema:isAccessibleForFree true
30 schema:isPartOf N00c9bb6562c84dda81cc41f531180752
31 N26e549efda96480f97544de2e057ce61
32 sg:journal.1297499
33 schema:name An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis
34 schema:pagination 84
35 schema:productId N3d4d8c2300884e8ead8f21f670abd1a7
36 N77fb391afa25409c9147a9ccbee51c3e
37 N80bf4c3e0f014b8e8c7e0e21bc65540d
38 N8a59392ad12b4b52b719193397c3771a
39 Nbe584676b3524ef1ab0c1a5648e6df95
40 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113057001
41 https://doi.org/10.1186/s13075-019-1857-3
42 schema:sdDatePublished 2019-04-16T06:25
43 schema:sdLicense https://scigraph.springernature.com/explorer/license/
44 schema:sdPublisher Ne479eebbeb4c4266ba513b440b13d407
45 schema:url https://link.springer.com/10.1186%2Fs13075-019-1857-3
46 sgo:license sg:explorer/license/
47 sgo:sdDataset articles
48 rdf:type schema:ScholarlyArticle
49 N00c9bb6562c84dda81cc41f531180752 schema:volumeNumber 21
50 rdf:type schema:PublicationVolume
51 N08b79a9cac4847dabb31ad77a6ef6c8a rdf:first N5c191cdb1cce4f95a5a9213ae7c4cc84
52 rdf:rest Nd8bb7a1740ff4cb9a556055c78d09747
53 N26e549efda96480f97544de2e057ce61 schema:issueNumber 1
54 rdf:type schema:PublicationIssue
55 N30fcc79667a34adab452df754d690189 schema:affiliation https://www.grid.ac/institutes/grid.417886.4
56 schema:familyName Wang
57 schema:givenName Hui
58 rdf:type schema:Person
59 N3d4d8c2300884e8ead8f21f670abd1a7 schema:name pubmed_id
60 schema:value 30922373
61 rdf:type schema:PropertyValue
62 N524bca3f380547168ca5218e7906dfcf schema:affiliation https://www.grid.ac/institutes/grid.490547.b
63 schema:familyName Matsumoto
64 schema:givenName Alan
65 rdf:type schema:Person
66 N5c191cdb1cce4f95a5a9213ae7c4cc84 schema:affiliation https://www.grid.ac/institutes/grid.144756.5
67 schema:familyName Pablos
68 schema:givenName Jose L.
69 rdf:type schema:Person
70 N5c9552419b24410a92d2e1a942eb940b schema:affiliation N6ed9b76bcbad4bfe98737ff28addba7a
71 schema:familyName Müller
72 schema:givenName Gerard Anton
73 rdf:type schema:Person
74 N64682f6d85ed4f0080066cb0677df586 rdf:first N99fa6ce6c60f47a0b6c9074abdab68ec
75 rdf:rest N8e24157a41ef44059b5084e43f6d4ec3
76 N6ed9b76bcbad4bfe98737ff28addba7a schema:name Abteilung.für Nephrologie und Rheumatologie, Göttingen, Germany
77 rdf:type schema:Organization
78 N77fb391afa25409c9147a9ccbee51c3e schema:name nlm_unique_id
79 schema:value 101154438
80 rdf:type schema:PropertyValue
81 N80bf4c3e0f014b8e8c7e0e21bc65540d schema:name doi
82 schema:value 10.1186/s13075-019-1857-3
83 rdf:type schema:PropertyValue
84 N8a59392ad12b4b52b719193397c3771a schema:name dimensions_id
85 schema:value pub.1113057001
86 rdf:type schema:PropertyValue
87 N8e24157a41ef44059b5084e43f6d4ec3 rdf:first N30fcc79667a34adab452df754d690189
88 rdf:rest Nb61d8c9cc0cd411dbb3357d93b6034ea
89 N9972dfbea9f04778b40106670a11643a rdf:first N5c9552419b24410a92d2e1a942eb940b
90 rdf:rest Ne94e1cbb010c4155801f52473a8b2ef3
91 N99fa6ce6c60f47a0b6c9074abdab68ec schema:affiliation Nbba58accf7f54ab0a2b631d4c00b343a
92 schema:familyName Kivitz
93 schema:givenName Alan
94 rdf:type schema:Person
95 Nb61d8c9cc0cd411dbb3357d93b6034ea rdf:first Nd71b7b52594444fe995a7d46029defbe
96 rdf:rest rdf:nil
97 Nbba58accf7f54ab0a2b631d4c00b343a schema:name Abteilung für Nephrologie und Rheumatologie, Göttingen, Germany
98 rdf:type schema:Organization
99 Nbe584676b3524ef1ab0c1a5648e6df95 schema:name readcube_id
100 schema:value 9c2f7819fbddef15635892850b461d152ea07841efcdb7f2f174243af446fe38
101 rdf:type schema:PropertyValue
102 Nd6a2a1c83b684a2d810fcb954459a735 schema:affiliation https://www.grid.ac/institutes/grid.418965.7
103 schema:familyName Pavelka
104 schema:givenName Karel
105 rdf:type schema:Person
106 Nd71b7b52594444fe995a7d46029defbe schema:affiliation https://www.grid.ac/institutes/grid.417886.4
107 schema:familyName Krishnan
108 schema:givenName Eswar
109 rdf:type schema:Person
110 Nd8bb7a1740ff4cb9a556055c78d09747 rdf:first Nd6a2a1c83b684a2d810fcb954459a735
111 rdf:rest N9972dfbea9f04778b40106670a11643a
112 Ndb3cd92bb1504673934c3101d35fc0e0 rdf:first Ndbed12debc1442a897aacb9618f1b5c2
113 rdf:rest N08b79a9cac4847dabb31ad77a6ef6c8a
114 Ndbed12debc1442a897aacb9618f1b5c2 schema:affiliation https://www.grid.ac/institutes/grid.477482.a
115 schema:familyName Cohen
116 schema:givenName Stanley
117 rdf:type schema:Person
118 Ne479eebbeb4c4266ba513b440b13d407 schema:name Springer Nature - SN SciGraph project
119 rdf:type schema:Organization
120 Ne94e1cbb010c4155801f52473a8b2ef3 rdf:first N524bca3f380547168ca5218e7906dfcf
121 rdf:rest N64682f6d85ed4f0080066cb0677df586
122 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
123 schema:name Medical and Health Sciences
124 rdf:type schema:DefinedTerm
125 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
126 schema:name Clinical Sciences
127 rdf:type schema:DefinedTerm
128 sg:journal.1297499 schema:issn 1478-6354
129 1478-6362
130 schema:name Arthritis Research & Therapy
131 rdf:type schema:Periodical
132 sg:pub.10.1007/s11926-016-0601-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040002812
133 https://doi.org/10.1007/s11926-016-0601-0
134 rdf:type schema:CreativeWork
135 sg:pub.10.1007/s40259-016-0184-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038300105
136 https://doi.org/10.1007/s40259-016-0184-3
137 rdf:type schema:CreativeWork
138 sg:pub.10.1007/s40259-016-0185-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042463549
139 https://doi.org/10.1007/s40259-016-0185-2
140 rdf:type schema:CreativeWork
141 sg:pub.10.1007/s40259-017-0218-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085050557
142 https://doi.org/10.1007/s40259-017-0218-5
143 rdf:type schema:CreativeWork
144 sg:pub.10.1186/ar3147 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024364202
145 https://doi.org/10.1186/ar3147
146 rdf:type schema:CreativeWork
147 https://app.dimensions.ai/details/publication/pub.1078771680 schema:CreativeWork
148 https://app.dimensions.ai/details/publication/pub.1106025459 schema:CreativeWork
149 https://doi.org/10.1002/1529-0131(199809)41:9<1552::aid-art5>3.0.co;2-w schema:sameAs https://app.dimensions.ai/details/publication/pub.1017993092
150 rdf:type schema:CreativeWork
151 https://doi.org/10.1002/art.22214 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009901742
152 rdf:type schema:CreativeWork
153 https://doi.org/10.1016/0049-0172(90)90060-s schema:sameAs https://app.dimensions.ai/details/publication/pub.1045775208
154 rdf:type schema:CreativeWork
155 https://doi.org/10.1016/j.jaad.2016.12.014 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084083514
156 rdf:type schema:CreativeWork
157 https://doi.org/10.1016/j.semarthrit.2015.04.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037699729
158 rdf:type schema:CreativeWork
159 https://doi.org/10.1016/j.semarthrit.2016.01.001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032526040
160 rdf:type schema:CreativeWork
161 https://doi.org/10.1016/j.semarthrit.2016.01.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012251139
162 rdf:type schema:CreativeWork
163 https://doi.org/10.1093/rheumatology/ker124 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012965699
164 rdf:type schema:CreativeWork
165 https://doi.org/10.1093/rheumatology/ket260 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000218995
166 rdf:type schema:CreativeWork
167 https://doi.org/10.1111/bjd.15857 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090920617
168 rdf:type schema:CreativeWork
169 https://doi.org/10.1136/annrheumdis-2016-209166 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023109204
170 rdf:type schema:CreativeWork
171 https://doi.org/10.1136/annrheumdis-2016-210459 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085872012
172 rdf:type schema:CreativeWork
173 https://doi.org/10.1586/1744666x.2015.1090313 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013216059
174 rdf:type schema:CreativeWork
175 https://www.grid.ac/institutes/grid.144756.5 schema:alternateName Hospital Universitario 12 De Octubre
176 schema:name Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain
177 rdf:type schema:Organization
178 https://www.grid.ac/institutes/grid.417886.4 schema:alternateName Amgen (United States)
179 schema:name Biosimilars Development, Amgen Inc., Thousand Oaks, CA, USA
180 rdf:type schema:Organization
181 https://www.grid.ac/institutes/grid.418965.7 schema:alternateName Revmatologický ústav
182 schema:name Institute of Rheumatology, Prague 2, Czech Republic
183 rdf:type schema:Organization
184 https://www.grid.ac/institutes/grid.477482.a schema:alternateName Metroplex Clinical Research Center
185 schema:name Internal Medicine, Rheumatology Division, Metroplex Clinical Research Center, 8144 Walnut Hill Lane, Suite 800, 75231, Dallas, TX, USA
186 rdf:type schema:Organization
187 https://www.grid.ac/institutes/grid.490547.b schema:alternateName Arthritis and Rheumatism Associates
188 schema:name Arthritis and Rheumatism Associates, Wheaton, MD, USA
189 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...